000 01258 a2200337 4500
005 20250516185907.0
264 0 _c20140918
008 201409s 0 0 eng d
022 _a1098-6596
024 7 _a10.1128/AAC.01651-13
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAarnoutse, Rob
245 0 0 _aReply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".
_h[electronic resource]
260 _bAntimicrobial agents and chemotherapy
_c2014
300 _a629-30 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAntitubercular Agents
_xpharmacokinetics
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aIsoniazid
_xpharmacokinetics
650 0 4 _aMale
650 0 4 _aPyrazinamide
_xpharmacokinetics
650 0 4 _aRifampin
_xpharmacokinetics
650 0 4 _aTuberculosis, Pulmonary
_xdrug therapy
700 1 _aRuesen, Carolien
700 1 _aBurhan, Erlina
700 1 _avan Crevel, Reinout
700 1 _aRuslami, Rovina
773 0 _tAntimicrobial agents and chemotherapy
_gvol. 58
_gno. 1
_gp. 629-30
856 4 0 _uhttps://doi.org/10.1128/AAC.01651-13
_zAvailable from publisher's website
999 _c23391074
_d23391074